HALF: Prospective multi-centre phase II clinical trial
evaluating the efficacy and safety of tyrosine kinase
inhibitors discontinuation after two-step dose reduction in
patients with chronic myeloid leukemia in deep molecular
remission.

a 2022

HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.

ŽÁČKOVÁ, Daniela; Petra ČIČÁTKOVÁ; Edgar FABER; Lukáš STEJSKAL; Michal KARAS et al.

Základní údaje

Originální název

HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.

Autoři

Vydání

22. Pražské hematologické dny Hematologie 2022, Praha, 2022

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30205 Hematology

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/22:00127206

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Tyrosine Kinase Inhibitors' Discontinuation; Two-Step Dose Reduction; Chronic Myeloid Leukemia

Štítky

rivok

Změněno: 5. 4. 2023 13:52, Mgr. Tereza Miškechová

Anotace

V originále

Treatment-free remission (TFR) has become a new treatment goal for chronic myeloid leukemia (CML) patients. However, usually abrupt tyrosine kinase inhibitors (TKIs) therapy discontinuation has been successful only in about half of eligible patients and it can cause burdening TKI withdrawal syndrome (TWS) in about 30% of them. Moreover, any robust clinical or biological factor predictive for successful TFR has not been identified yet. On top of that, sustainable deep molecular response (DMR) as the main prerequisite for TKI discontinuation attempt is achieved only in 20-40% of patients. The majority of CML patients, therefore, need to be treated with the effective and well-tolerated drug for a long time or even life-long.

Návaznosti

90128, velká výzkumná infrastruktura

Název: CZECRIN III

Citovat

ŽÁČKOVÁ, Daniela; Petra ČIČÁTKOVÁ; Edgar FABER; Lukáš STEJSKAL; Michal KARAS; Petra BĚLOHLÁVKOVÁ; Hana KLAMOVÁ; Olga ČERNÁ; Eduard CMUNT; Lukáš SEMERÁD; Tomáš HORŇÁK; Anežka KVETKOVÁ; Jiřina PROCHÁZKOVÁ; Jitka RYCHLÍČKOVÁ; Radka ŠTĚPÁNOVÁ; Adam SVOBODNÍK; Kateřina MACHOVÁ POLÁKOVÁ; Ivana JEŽÍŠKOVÁ; Tomáš JURČEK; Marek BORSKÝ; O. VIEWIORKA; Regina DEMLOVÁ a Jiří MAYER. HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission. In 22. Pražské hematologické dny Hematologie 2022, Praha. 2022.

@proceedings{2233293,
   author = {Žáčková, Daniela and Čičátková, Petra and Faber, Edgar and Stejskal, Lukáš and Karas, Michal and Bělohlávková, Petra and Klamová, Hana and Černá, Olga and Cmunt, Eduard and Semerád, Lukáš and Horňák, Tomáš and Kvetková, Anežka and Procházková, Jiřina and Rychlíčková, Jitka and Štěpánová, Radka and Svobodník, Adam and Machová Poláková, Kateřina and Ježíšková, Ivana and Jurček, Tomáš and Borský, Marek and Viewiorka, O. and Demlová, Regina and Mayer, Jiří},
   booktitle = {22. Pražské hematologické dny Hematologie 2022, Praha},
   keywords = {Tyrosine Kinase Inhibitors' Discontinuation; Two-Step Dose Reduction; Chronic Myeloid Leukemia},
   language = {eng},
   title = {HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.},
   year = {2022}
}

TY  - CONF
ID  - 2233293
AU  - Žáčková, Daniela - Čičátková, Petra - Faber, Edgar - Stejskal, Lukáš - Karas, Michal - Bělohlávková, Petra - Klamová, Hana - Černá, Olga - Cmunt, Eduard - Semerád, Lukáš - Horňák, Tomáš - Kvetková, Anežka - Procházková, Jiřina - Rychlíčková, Jitka - Štěpánová, Radka - Svobodník, Adam - Machová Poláková, Kateřina - Ježíšková, Ivana - Jurček, Tomáš - Borský, Marek - Viewiorka, O. - Demlová, Regina - Mayer, Jiří
PY  - 2022
TI  - HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.
KW  - Tyrosine Kinase Inhibitors' Discontinuation
KW  - Two-Step Dose Reduction
KW  - Chronic Myeloid Leukemia
N2  - Treatment-free remission (TFR) has become a new treatment goal for chronic myeloid leukemia (CML) patients. However, usually abrupt tyrosine kinase inhibitors (TKIs) therapy discontinuation has been successful only in about half of eligible patients and it can cause burdening TKI withdrawal syndrome (TWS) in about 30% of them. Moreover, any robust clinical or biological factor predictive for successful TFR has not been identified yet. On top of that, sustainable deep molecular response (DMR) as the main prerequisite for TKI discontinuation attempt is achieved only in 20-40% of patients. The majority of CML patients, therefore, need to be treated with the effective and well-tolerated drug for a long time or even life-long.
ER  -

ŽÁČKOVÁ, Daniela; Petra ČIČÁTKOVÁ; Edgar FABER; Lukáš STEJSKAL; Michal KARAS; Petra BĚLOHLÁVKOVÁ; Hana KLAMOVÁ; Olga ČERNÁ; Eduard CMUNT; Lukáš SEMERÁD; Tomáš HORŇÁK; Anežka KVETKOVÁ; Jiřina PROCHÁZKOVÁ; Jitka RYCHLÍČKOVÁ; Radka ŠTĚPÁNOVÁ; Adam SVOBODNÍK; Kateřina MACHOVÁ POLÁKOVÁ; Ivana JEŽÍŠKOVÁ; Tomáš JURČEK; Marek BORSKÝ; O. VIEWIORKA; Regina DEMLOVÁ a Jiří MAYER. HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission. In \textit{22. Pražské hematologické dny Hematologie 2022, Praha}. 2022.

Přehled o publikaci